

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/786,400	02/24/2004	Alexander William Oxford	56476-DIV2 (71661) 2879	
21874	7590 11/02/2005		EXAMINER	
EDWARDS & ANGELL, LLP			TRUONG, TAMTHOM NGO	
P.O. BOX 55874 BOSTON, MA 02205			ART UNIT	PAPER NUMBER
,			1624	

DATE MAILED: 11/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

ł.						
		Application No.	Applicant(s)			
Office Addition Occur		10/786,400	OXFORD ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Tamthom N. Truong	1624			
Period fo	The MAILING DATE of this communication apports. The ply	pears on the cover sheet with the c	orrespondence address			
THE - Exte after - If the - If NO - Failt Any	IORTENED STATUTORY PERIOD FOR REPLIMAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a replication of the provision of the provisio	136(a). In no event, however, may a reply be tin ly within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	nely filed  s will be considered timely. the mailing date of this communication.  10 (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on 12 A	ugust 2005.				
2a)⊠	This action is <b>FINAL</b> . 2b) This	s action is non-final.				
3)□	,—					
Disposit	ion of Claims					
5)□ 6)⊠ 7)□	Claim(s) 43-48,51 and 52 is/are pending in the 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) 43-48, 51 and 52 is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or	wn from consideration.				
Applicati	ion Papers					
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	∍ 37 CFR 1.85(a).			
11)	Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex					
Priority ι	under 35 U.S.C. § 119					
a)(	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the priority documents  application from the International Bureau  See the attached detailed Office action for a list	s have been received. s have been received in Application rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
3	See the attached detailed Office action for a list	or the certified copies not receive	u.			
Attachman	*/c\					
Attachmeni 1) ☐ Notic	t(s) e of References Cited (PTO-892)	4) X Interview Summary	(PTO-413)			
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ite. <u>attached</u> .			
3) 🔲 Inform	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal P	atent Application (PTO-152)			

## FINAL ACTION

Applicant's amendment of 8-12-05 has been fully considered. The amended claims 43-45 have not overcome the previous rejection of 112/1<sup>st</sup> paragraph by replacing the term "prevention" with the phrase "acute or prophylactic". Thus, the previous enablement rejection for "prevention" is maintained herein.

The deletion of "OCH<sub>2</sub>" from the definition of X has overcome the previous "scope of enablement" rejection, and so, said rejection is withdrawn herein.

The deletion of the limitation of " $R^1$  and  $R^2$  are the same as each other", and the limitation of " $R^7$  and  $R^8$  are the same as each other" has overcome the previous rejection of  $112/2^{nd}$  paragraph.

Claims 1-42, 49 and 50 have been cancelled.

Claims 43-48, 51 and 52 are pending.

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

**Enablement:** Claims 43-48, 51 and 52 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the

art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claims 43-45 have been amended with the language of a "method for the acute or prophylactic treatment of a disease..." The term "prophylactic" suggests "preventing on anticipation" which is meant for preventing a pathophysiological condition that is resulted from a medical procedure (e.g., surgery), or exposure to certain environment (e.g., high elevation, or polluted area). However, a disease related to a phosphodiesterase isoenzyme" is usually a chronic disease such as: asthma, chronic obstructive pulmonary disease (COPD), or arthritis, etc. Thus, it is unclear how a compound can prophylactically treat such a disease since the duration of said diseases is indefinite. The specification does not describe a protocol for a "prophylactic treatment" of a disease related to "phosphodiesterase isoenzyme". Thus, the specification fails to enable a "prophylactic treatment" as recited in said claims.

Claims 46-48, 51 and 52 are rejected as being dependent on claims 43-45.

## Telephone Interview

A telephone interview was conducted on 10-26-05 with Ms. Christine O'Day to resolve the enablement issue above. However, due to applicant's unavailability, no agreement could be reached.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1624

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M-F (9:30-6:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Tamthom N. Truong

Examiner

Art Unit 1624

10-27-05

Kernsom prient Evalener Texandlogy Center 1610